May Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
Manufacturer's Night, includes dinner and corporate posters. Please RSVP by May 4.
ACS Philadelphia Section,
- Topic: "High Throughput Mass Spectrometry in the Age of High Throughput Drug Discovery"
- Speaker: D.B. Kassel, DuPont Pharmaceuticals Research Labs, San Diego, CA 92121
- Date: Monday, May 14, 2001. 6:00 PM
- Time: 6:00 Buffet Dinner hosted by Micromass and Waters
7:00 Socializing/Vendors presentations
- RSVP for the Dinner to Scott Van Bramer by May 4.
- Place: Merck, West Point, 37 Auditorium
Combinatorial chemistry and automated parallel synthesis, now mainstays in the pharmaceutical, biotechnology, agrochemical and material science industries, have forced the analytical community to develop technologies to keep pace. The conundrum facing the analytical community is that analytical techniques are inherently serial-based and parallel synthesis techniques are inherently parallel. Over the past few years, the analytical community has addressed this conundrum by introducing a new wave of cutting edge technology to support combinatorial library characterization, purification and screening. This presentation will cover state-of-the-art LC/MS and SFC/MS methods for the high throughput mass spectrometric analysis, quantification and purification (mass- and UV-directed fractionation) of combinatorial and parallel synthesis libraries. Additionally, methods where MS is being applied to the study of receptor:ligand and enzyme:substrate interactions will be presented. Emerging technologies, including high throughput absorption, metabolism screening and high throughput parallel analysis will be presented.
Dr. Kassel received his Ph.D. in Analytical Chemistry at Michigan State University in 1988. Directly following, he held a post doctoral fellowship at The Massachusetts Institute of Technology studying under the tutelage of Professor Klaus Biemann. In addition, Dr. Kassel was a recipient of a two-year NIH National Research Service Award fellowship in the Departments of Molecular Biology and Human Genetics at Harvard University. Following his post-doctoral studies, Dr. Kassel joined Glaxo Wellcome, Inc. where he held, over the course of his tenure, steadily increasing roles of responsibility within the Departments of Bioanalytical & Structural Chemistry. During this time, he pioneered the coupling of perfusion chromatography and mass spectrometry for the rapid characterization of proteins and enzyme digests and applied the technology to elucidate the role of phosphorylation in protein signaling pathways. Dr. Kassel also published one of the first papers coupling affinity column chromatography with capillary LC/MS for the analysis and quantification phosphoprotein:phosphopeptide and protein:ligand interactions.
In the late part of 1995, Dr. Kassel joined CombiChem, Inc. as Director of Analytical Technologies. His research team developed state-of-the-art analytical tools to aid the drug discovery process. His seminal contributions to the field of combinatorial chemistry have included the design, development and implementation of automated preparative HPLC/MS for the purification of compound libraries. In addition, his team developed an array of parallel HPLC/MS systems for ultra-high throughput analysis, purification and in vitro ADME profiling of combinatorial libraries. Dr. Kassel has co-authored more than 40 papers, principally in the area of LC/MS, serves as a reviewer for many journals, and is editorial board member of Combinatorial Chemistry & High Throughput Screening. He has been an invited speaker at numerous conferences both nationally and internationally, has chaired several mass spectrometry conferences and organized several short courses and workshops, including the well-received ASMS short courses on "Mass Spectrometry of Peptides and Proteins" and "Mass Spectrometry and Combinatorial Chemistry."
In November of 1999, CombiChem, Inc. was acquired by Dupont Pharmaceuticals, maintaining west-coast operations in sunny San Diego. Dr. Kassel and his team continue to develop state-of-the-art technology for drug discovery. Recent efforts have focussed on increasing sample throughput for analysis, purification and in vitro ADME profiling of compound libraries. A major emphasis has been placed on developing and implementing high throughput ADME assays and parallel analysis tools to accelerate drug discovery. In addition, exciting developments in supercritical fluid chromatography-MS as a complement to HPLC/MS have been made for the high throughput analysis and purification of compound libraries.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated Monday, April 24, 2000 10:37:55 AM